Insider · CIK 0001836218
Louise Rodino-Klapac
Files at SRPT (Sarepta Therapeutics, Inc.). First filing -, latest -.
In brief
Louise Rodino-Klapac files SEC Form 4 as president at SRPT (Sarepta Therapeutics, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Louise Rodino-Klapac has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 15 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 4, 2026 | SRPT Sarepta Therapeutics, Inc. | FTax withholding Common Stock | -21,423 | $22.22 | $476k | 203,900 | 35 d ago |
| Mar 11, 2026 | SRPT Sarepta Therapeutics, Inc. | FTax withholding Common Stock | -948 | $17.03 | $16k | 225,323 | Mar 13, 2026 |
| Mar 9, 2026 | SRPT Sarepta Therapeutics, Inc. | FTax withholding Common Stock | -504 | $16.95 | $8,543 | 227,166 | Mar 11, 2026 |
| Mar 9, 2026 | SRPT Sarepta Therapeutics, Inc. | FTax withholding Common Stock | -895 | $16.95 | $15k | 226,271 | Mar 11, 2026 |
| Mar 1, 2026 | SRPT Sarepta Therapeutics, Inc. | MOption exercise Common Stock | +8,125 | - | - | 232,155 | Mar 3, 2026 |
| Mar 2, 2026 | SRPT Sarepta Therapeutics, Inc. | FTax withholding Common Stock | -3,718 | $16.20 | $60k | 228,437 | Mar 3, 2026 |
| Mar 2, 2026 | SRPT Sarepta Therapeutics, Inc. | FTax withholding Common Stock | -767 | $16.20 | $12k | 227,670 | Mar 3, 2026 |
| Mar 1, 2026 | SRPT Sarepta Therapeutics, Inc. | MOption exercise Performance Stock Unitsderivative | -8,125 | $0.00 | $0 | 0 | Mar 3, 2026 |
| Feb 25, 2026 | SRPT Sarepta Therapeutics, Inc. | AGrant or award Performance Stock Unitsderivative | +1,875 | - | - | 8,125 | Feb 27, 2026 |
| Nov 17, 2025 | SRPT Sarepta Therapeutics, Inc. | FTax withholding Common Stock | -4,582 | $18.42 | $84k | 224,030 | Nov 19, 2025 |
| Sep 3, 2025 | SRPT Sarepta Therapeutics, Inc. | AGrant or award Common Stock | +93,875 | $0.00 | $0 | 178,612 | Sep 5, 2025 |
| Sep 3, 2025 | SRPT Sarepta Therapeutics, Inc. | AGrant or award Common Stock | +50,000 | $0.00 | $0 | 228,612 | Sep 5, 2025 |
| Aug 5, 2025 | SRPT Sarepta Therapeutics, Inc. | AGrant or award Performance Stock Unitsderivative | +6,250 | $0.00 | $0 | 6,250 | Aug 6, 2025 |
| Nov 18, 2024 | SRPT Sarepta Therapeutics, Inc. | FTax withholding Common Stock | -4,558 | $102.89 | $469k | 67,630 | Nov 20, 2024 |
| Nov 17, 2023 | SRPT Sarepta Therapeutics, Inc. | FTax withholding Common Stock | -4,508 | $82.98 | $374k | 65,751 | Nov 20, 2023 |
Questions about Louise Rodino-Klapac
Answered from the filings on this page, as of the latest one.
Is Louise Rodino-Klapac buying or selling?
Louise Rodino-Klapac has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Louise Rodino-Klapac's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Louise Rodino-Klapac has 0.
Where does Louise Rodino-Klapac file Form 4?
Louise Rodino-Klapac has filed Form 4 at SRPT (Sarepta Therapeutics, Inc.) as Head of R&D, CSO. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.